[1]
|
Kroemer, G., Marino, G. and Levine, B. (2010) Autophagy and the Integrated Stress Response. Molecular Cell, 40, 280-293. https://doi.org/10.1016/j.molcel.2010.09.023
|
[2]
|
Pickart, C.M. (2000) Ubiquitin in Chains. Trends in Biochemical Sciences, 25, 544-548.
https://doi.org/10.1016/S0968-0004(00)01681-9
|
[3]
|
Coleman, K.G. and Crews, C.M. (2018) Proteoly-sis-Targeting Chimeras: Harnessing the Ubiquitin-Proteasome System to Induce Degradation of Specific Target Proteins. Annual Review of Cancer Biology, 2, 41-58.
https://doi.org/10.1146/annurev-cancerbio-030617-050430
|
[4]
|
Martin-Acosta, P. and Xiao, X. (2021) PROTACs to Address the Challenges Facing Small Molecule Inhibitors. European Journal of Medicinal Chemistry, 210, Article ID: 112993. https://doi.org/10.1016/j.ejmech.2020.112993
|
[5]
|
Soltan, O.M., Shoman, M.E., Abdel-Aziz, S.A., et al. (2021) Molecular Hybrids: A Five-Year Survey on Structures of Multiple Targeted Hybrids of Protein Kinase Inhibitors for Cancer Therapy. European Journal of Medicinal Chemistry, 225, Article ID: 113768. https://doi.org/10.1016/j.ejmech.2021.113768
|
[6]
|
Yang, Y.Q., Gao, H.Y., Sun, X.Y., et al. (2020) Global PROTAC Toolbox for Degrading BCR-ABL Overcomes Drug-Resistant Mutants and Adverse Effects. Journal of Me-dicinal Chemistry, 63, 8567-8583.
https://doi.org/10.1021/acs.jmedchem.0c00967
|
[7]
|
Jiang, L., Wang, Y.T., Li, Q., et al. (2021) Design, Synthesis, and Biological Evaluation of Bcr-Abl PROTACs to Overcome T315I Mutation. Acta Pharmaceutica Sinica B, 11, 1315-1328. https://doi.org/10.1016/j.apsb.2020.11.009
|
[8]
|
Liu, H.X., Ding, X.Y., Liu, L.Y., et al. (2021) Dis-covery of Novel BCR-ABL PROTACs Based on the Cereblon E3 Ligase Design, Synthesis, and Biological Evaluation. European Journal of Medicinal Chemistry, 223, Article ID: 113645. https://doi.org/10.1016/j.ejmech.2021.113645
|
[9]
|
Crews, C., Toure, M., Ko, E., et al. (2017) Proteolysis Target-ing Chimera Compounds and Methods of Preparing and Using Same. Patent WO2017079267A1.
|
[10]
|
Lai, A.C., Toure, M., Hellerschmied, D., Salami, J., Jaime-Figueroa, S., Ko, E., Hines, J. and Crews, C.M. (2016) Modular PROTAC De-sign for the Degradation of Oncogenic BCR-ABL. Angewandte Chemie International Edition in English, 55, 807-810. https://doi.org/10.1002/anie.201507634
|
[11]
|
Gabizon, R. and London, N. (2020) A Fast and Clean BTK Inhibitor. Journal of Medicinal Chemistry, 63, 5100-5101.
https://doi.org/10.1021/acs.jmedchem.0c00597
|
[12]
|
Tasso, B., Spallarossa, A., Russo, E. and Brullo, C. (2021) The Development of BTK Inhibitors: A Five-Year Update. Molecules, 26, 7411. https://doi.org/10.3390/molecules26237411
|
[13]
|
ShorerArbel, Y., Katz, B.-Z., Gabizon, R., Shraga, A., Bronstein, Y., Kamdjou, T., Globerson Levin, A., Perry, C., Avivi, I., London, N. and Herishanu, Y. (2021) Proteolysis Targeting Chimeras for BTK Efficiently Inhibit B-Cell Receptor Signaling and Can Overcome Ibrutinib Resistance in CLL Cells. Frontiers in Oncology, 11, Article ID: 646971.
https://doi.org/10.3389/fonc.2021.646971
|
[14]
|
Sun, Y., Zhao, X., Ding, N., et al. (2018) PROTAC-Induced BTK Degradation as a Novel Therapy for Mutated BTK C481S Induced Ibrutinib-Resistant B-Cell Malignancies. Cell Re-search, 28, 779-781.
https://doi.org/10.1038/s41422-018-0055-1
|
[15]
|
Sun, Y., Ding, N., Song, Y., et al. (2019) Degradation of Bru-ton’s Tyrosine Kinase Mutants by PROTACs for Potential Treatment of Ibrutinib-Resistant Non-Hodgkin Lymphomas. Leukemia, 33, 2105-2110.
https://doi.org/10.1038/s41375-019-0440-x
|
[16]
|
Dobrovolsky, D., Wang, E.S., Morrow, S., Leahy, C., Faust, T., Nowak, R.P., Donovan, K.A., Yang, G., Li, Z.N., Fischer, E.S., Treon, S.P., Weinstock, D.M. and Gray, N.S. (2019) Bruton Tyrosine Kinase Degradation as a Therapeutic Strategy for Cancer. Blood, 133, 952-961. https://doi.org/10.1182/blood-2018-07-862953
|
[17]
|
Lu, Y. and Sun, H.Y. (2020) Progress in the Development of Small Molecular Inhibitors of Focal Adhesion Kinase (FAK). Journal of Medicinal Chemistry, 63, 14382-14403. https://doi.org/10.1021/acs.jmedchem.0c01248
|
[18]
|
Crews, C.M., Cromm, P.M. and Crew, A.P. (2020) Prepara-tion of Bifunctional Substituted Pyrimidines as Modulators of FAK Proteolyse. Patent WO2020023851A1.
|
[19]
|
Gray, N.S., Jiang, B., Nabet, B., et al. (2020) Degradation of FAK or FAC and ALK by Conjugation of FAC and ALK Inhibi-tors with E3 Ligase Ligands and Methods of Use. Patent WO2020069117A1.
|
[20]
|
Ito, K., Park, S.H., Katsyv, I., et al. (2017) PTK6 Regulates Growth and Survival of Endocrine Therapy-Resistant ER+ Breast Cancer Cells. NPJ Breast Cancer, 3, 45. https://doi.org/10.1038/s41523-017-0047-1
|
[21]
|
Gilic, M.B. and Tyner, A.L. (2020) Targeting Pro-tein Tyrosine Kinase 6 in Cancer. Biochimica et Biophysica Acta (BBA)—Reviews on Cancer, 1874, Article ID: 188432. https://doi.org/10.1016/j.bbcan.2020.188432
|
[22]
|
Jin, J., Irie, H., Liu, J., et al. (2020) Preparation as Heterocyclic Compounds as Protein Tyrosine Kinase 6 (PTK6) Degradation/Disruption Compounds and Methods of Use. Patent WO2020010204A1.
|
[23]
|
Matheson, C.J., Backos, D.S. and Reigan, P. (2016) Targeting WEE1 Kinase in Cancer. Trends in Pharmacological Sciences, 37, 872-881. https://doi.org/10.1016/j.tips.2016.06.006
|
[24]
|
Li, Z.N., Li, Z., Pinch, B.J., Olson, C.M., et al. (2020) Development and Characterization of a Wee1 Kinase Degrader. Cell Chemical Bi-ology, 27, 57-65.e9. https://doi.org/10.1016/j.chembiol.2019.10.013
|
[25]
|
Bennett, J. and Starczynowski, D.T. (2022) IRAK1 and IRAK4 as Emerging Therapeutic Targets in Hematologic Malignancies. Current Opinion in Hema-tology, 29, 8-19. https://doi.org/10.1097/MOH.0000000000000693
|
[26]
|
Mainolfi, N., Ji, N., Kluge, A.F., et al. (2020) Preparation of Bifunctional Compounds as IRAK Degraders and Uses Thereof. Patent WO2020113233A1.
|
[27]
|
Aoki, Y. and Matsubara, Y. (2013) Ras/MAPK Syndromes and Childhood Hemato-Oncological Diseases. International Journal of Hematologym, 97, 30-36. https://doi.org/10.1007/s12185-012-1239-y
|
[28]
|
Dietrich, J., Gokhale, V., Wang, X.D., et al. (2010) Application of a Novel [3+2] Cycloaddition Reaction to Prepare Substituted Imidazoles and Their Use in the Design of Potent DFG-Outallosteric B-Rafinhibitors. Bioorganic& Medicinal Chemistry, 18, 292-304. https://doi.org/10.1016/j.bmc.2009.10.055
|
[29]
|
Thabit, M.G., Mostafa, A.S., Selim, K.B., et al. (2020) Design, Synthesis and Molecular Modeling of Phenyl Dihydropyridazinone Derivatives as B-Raf Inhibitors with Anticancer Ac-tivity. Bioorganic Chemistry, 103, Article ID: 104148. https://doi.org/10.1016/j.bioorg.2020.104148
|
[30]
|
Crew, A.P., Hornberger, K.R., Wang, J., et al. (2020) Polycyclic Compounds and Methods for the Targeted Degradation of Rapidly Accelerated Fibrosarcoma Polypeptides. Patent WO2020051564A1.
|
[31]
|
Huang, J.H., Wang, X.R, Dong, R.N., et al. (2021) Discovery of N-(4-(3-isopropyl-2-methyl-2H-indazol-5-yl)pyrimidin- 2-yl)-4-(4-methylpiperazin-1-yl)quinazolin-7-amine as a Novel, Potent, and Oral Cyclin-Dependent Kinase Inhibitor against Haematological Malignancies. Journal of Medicinal Chemistry, 64, 12548-12571.
https://doi.org/10.1021/acs.jmedchem.1c00271
|
[32]
|
Freeman-Cook, K.D., Hoffman, R.L., Behenna, D.C., et al. (2021) Discovery of PF-06873600, a CDK2/4/6 Inhibitor for the Treatment of Cancer. Journal of Medicinal Chemistry, 64, 9056-9077.
|
[33]
|
Gray, N., Zhang, T., Olson, C.M., et al. (2017) Degradation of Cyclin-Dependent Kinase 9 (cdk9) by Conjugation of cdk9 Inhibitors with e3 Ligase Ligand and Methods of Use. Patent WO2017185031A1.
|
[34]
|
Gray, N.S., Jiang, B., Zhang, T., et al. (2020) Degradation of Cyclin-Dependent Kinase 4/6 (cdk4/6) by Conjugation of cdk4/6 Inhibitors with E3 Ligase Ligand and Methods of Use. Patent WO2020023480A1.
|
[35]
|
Salvino, J., Calabretta, B., De Dominici, M., et al. (2020) Preparation of Pyrimidine Derivatives as Proteolysis-Targeting Chimeras (PROTACs). Patent WO2020092662A1.
|
[36]
|
Gray, N., Zhang, T., Olson, C.M., et al. (2017) Degradation of Cyclin-Dependent Kinase 9 (cdk9) by Conjugation of cdk9 Inhibitors with E3 Ligase Ligand and Methods of Use. Patent WO2017185023A1.
|
[37]
|
Taft, J., Markson, M., Legarda, D., et al. (2021) Human TBK1 Deficiency Leads to Autoin-flammation Driven by TNF-Induced Cell Death. Cell, 184, 4447-4463.e20. https://doi.org/10.1016/j.cell.2021.07.026
|
[38]
|
Crew, A.P., Wang, J., Dong, H., et al. (2016) Preparation of PROTAC Compounds as TANK-Binding Kinase 1 Inhibitors for Modulation of Proteolysis and Associated Methods of Use. Patent WO2016197114A1.
|
[39]
|
Zheng, M.Z., Huo, J.F., Gu, X.X., et al. (2021) Rational Design and Synthesis of Novel Dual PROTACs for Simultaneous Degradation of EGFR and PARP. Journal of Medicinal Chemistry, 64, 7839-7852.
https://doi.org/10.1021/acs.jmedchem.1c00649
|